Multi-omics for COVID-19: driving development of therapeutics and vaccines

Mengyu Guo; Muya Xiong; Jinying Peng; Tong Guan; Haixia Su; Yanyi Huang; Cai-Guang Yang; Yang Li; Diana Boraschi; Thanigaimalai Pillaiyar; Guanbo Wang; Chengqi Yi; Yechun Xu; Chunying Chen

doi:10.1093/nsr/nwad161

Multi-omics for COVID-19: driving development of therapeutics and vaccines

Natl Sci Rev. 2023 May 30;10(9):nwad161. doi: 10.1093/nsr/nwad161. eCollection 2023 Sep.

Authors

Mengyu Guo¹, Muya Xiong^{2

3}, Jinying Peng⁴, Tong Guan^{1

3}, Haixia Su^{2

3}, Yanyi Huang^{5

6

7

8}, Cai-Guang Yang^{9

3}, Yang Li¹⁰, Diana Boraschi^{10

11}, Thanigaimalai Pillaiyar¹², Guanbo Wang^{5

6}, Chengqi Yi^{4

13

7}, Yechun Xu^{2

3}, Chunying Chen^{1

3

14}

Affiliations

¹ CAS Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety, and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China.
² State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
³ University of Chinese Academy of Sciences, Beijing 100049, China.
⁴ State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking University, Beijing 100871, China.
⁵ Biomedical Pioneering Innovation Centre, Peking University, Beijing 100871, China.
⁶ Institute for Cell Analysis, Shenzhen Bay Laboratory, Shenzhen 528107, China.
⁷ Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China.
⁸ College of Chemistry and Molecular Engineering, Beijing National Laboratory for Molecular Sciences, Peking University, Beijing 100871, China.
⁹ State Key Laboratory of Drug Research, Centre for Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
¹⁰ Laboratory of Immunology and Nanomedicine, and China-Italy Joint Laboratory of Pharmacobiotechnology for Medical Immunomodulation, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
¹¹ Institute of Biochemistry and Cell Biology, National Research Council, Napoli 80131, Italy.
¹² Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tuebingen Center for Academic Drug Discovery, Eberhard Karls University Tübingen, Tübingen 72076, Germany.
¹³ Department of Chemical Biology and Synthetic and Functional Biomolecules Center, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
¹⁴ GBA National Institute for Nanotechnology Innovation, Guangzhou 510700, China.

Abstract

The ongoing COVID-19 pandemic caused by SARS-CoV-2 has raised global concern for public health and economy. The development of therapeutics and vaccines to combat this virus is continuously progressing. Multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, epigenomics and metallomics, have helped understand the structural and molecular features of the virus, thereby assisting in the design of potential therapeutics and accelerating vaccine development for COVID-19. Here, we provide an up-to-date overview of the latest applications of multi-omics technologies in strategies addressing COVID-19, in order to provide suggestions towards the development of highly effective knowledge-based therapeutics and vaccines.

Keywords: COVID-19; SARS-CoV-2; antibodies; multi-omics; small-molecule drugs; vaccines.

Publication types

Review